About
Treatments for solid tumors and eye diseases
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodySan Diego & Southern California
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
501
By Phase
PHASE1/PHASE2: 3
By Status
RECRUITING: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT05652686Lead Sponsor
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
PHASE1/PHASE2Recruiting
203 participants
Started: Sep 5, 2023 · Completed: Aug 31, 2028
NCT05482893Lead Sponsor
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
PHASE1/PHASE2Recruiting
258 participants
Started: Mar 15, 2023 · Completed: Apr 30, 2028
NCT05431270Lead Sponsor
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
PHASE1/PHASE2Recruiting
40 participants
Started: Aug 11, 2022 · Completed: Aug 31, 2028
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...